Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical...

Area of Science:

• Cardiology
• Molecular Biology
• Medical Imaging

Background:

• Acute myocardial infarction (MI) triggers inflammatory responses that contribute to adverse cardiac remodeling.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a role in lipid metabolism and inflammation.
• Evolocumab is a monoclonal antibody targeting PCSK9.

Purpose of the Study:

• To investigate the effect of evolocumab on myocardial inflammation in patients following acute MI.
• To explore the relationship between PCSK9 levels, inflammation, and cardiac remodeling post-MI.

Main Methods:

• A randomized trial involving 55 participants from the EVACS trials with non-ST-segment elevation MI or ST-segment elevation MI.
• Participants received a single dose of evolocumab or placebo.
• Myocardial inflammation was assessed using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scans at baseline and 30 days.

Main Results:

• Evolocumab significantly reduced myocardial inflammation (mean standardized uptake value, SUVmean) compared to placebo.
• PCSK9 levels at 30 days correlated with SUVmean.
• Higher SUVmean was associated with increased end-systolic volume at 6 months.

Conclusions:

• Early PCSK9 inhibition with evolocumab effectively reduces post-MI myocardial inflammation.
• PCSK9 inhibition may influence cardiac remodeling in the months after an acute coronary event.